Sukhmani Kaur Padda, MD

Sukhamni Padda cropped
​​
This physician is not currently rated. Why?

Why is this doctor not rated?

Close

To ensure the accuracy of our patient satisfaction scores, we require that providers who see patients receive a minimum number of completed patient-submitted surveys before their reviews are listed on their profiles. Star ratings on this site are collected on a rolling basis from the previous 12 months.
Additionally, some of the physicians listed on our site do not see patients directly, and therefore, do not receive evaluation and ratings from patients.

More about patient ratings

Professor, Clinical Investigator Track, Thoracic and Phase I Oncology

Vice Chair of Medical Oncology, Fox Chase Cancer Center at Temple University Hospital

Treatment Focus

Medical Oncology

Thoracic and Phase I Clinical Oncology

Lung Neuroendocrine/Carcinoids

Clinical Locations

Educational Background

  • 2001-2003: B.S., Natural Sciences and Minor in Chemistry, University of Akron, Akron, OH Major Natural Sciences, Minor Chemistry, Summa Cum Laude and Dean's List
  • 2003-2007: M.D., Northeast Ohio Medical University (NEOMED), Rootstown, OH
  • 2008-2011: Residency, Internal Medicine, Stanford University, Stanford, CA
  • 2011-2014: Fellowship, Medical Hematology/Oncology, Stanford University, Stanford, CA


 




 

Certifications

2012:  American Board of Internal Medicine-Certified
2014:  American Board of Internal Medicine-Medical Oncology Certified
 

Memberships

  • Aug 2011:  Amecican Society of Clinical Oncology (ASCO)
  • Jan 2013:  International Association for the Study of Lung Cancer (IASLC)
  • July 2013   American Association for Cancer Research (AACR)
  • Aug 2013:  International Thymic Malignancy Interest Group (ITMIG)
  • Oct 2015:  Eastern Cooperative Oncology Group (ECOG)-ACRIN
  • Jul  2016:  North American Neurocndocrinc Tumor Society (NANETS)
  • Aug 2016:  Society of Immunotherapy for Cancer (SITC)
  • Aug 2021:  American College of Physicians (ACP)

Honors & Awards

  • Jun 2007:  STERIS Award for Infectious Disease, Northeast Ohio Medical University (NEOMED), Rootstown, OH
  • Sep 2014:  International Thymic Malignancy Interest Group Travel Grant, The 5th International Thymic Malignancy Interest Group Annual Meeting, Antwerp, Belgium
  • Sep 2014:  Masaoka Award for Best Oral Abstract, The 5th International Thymic Malignancy Interest Group Annual Meeting, Antwerp, Belgium 
  • Mar 2016:  prIME Oncology Young Investigator Award in Non-Small Cell Lung Cancer (Top 5 Oral Abstract), 4th Annual Young Investigators Forum in Lung Cancer, Chicago, IL
  • Jul2016:  NorCal CarciNET Community Travel Award, 9•• Annual Multidisciplinary Neuroendocrinc Tumor Symposium, Jackson, Wyoming 
  • Nov 2016:  Society of lmmunotherapy for Cancer Travel Award, Society of Immunotherapy for Cancer, National Harbor, Maryland
  • Mar 2019:  Department of Medicine Teaching Award, Stanford University, Stanford, CA
  • 2020-2021:  Stanford Cancer Institute (SCI) Cancer Innovation Award (PI)

 






 

Research Interests

I am a medical oncologist speeializing in interventional clinical trials and translational research in thoracic oncology. My clinical research focuses on targeted therapeutics in genomic subsets of non-small cell lung cancer (NSCLC), including epidermal growth factor receptor (EGFR) mutated and Kirsten rat sarcoma viral (KRAS) mutated subsets. I have expertise in two rare thoracic malignancies including thymic malignancies and lung neuroendocrine tumors.

Selected Publications

1. Waliany S, Zhu H, Wakelee H, Padda SK, Das M, Ramchandran K, Myall NJ, Chen T, Witteles RM, Neal JW. Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. J Thorne Oncol. 2021 Aug 18:SI556-0864(21)02377-7.  doi: 10.1016/j.jtho.2021.07.030. Online ahead of print. PMID: 34418561
2. Gencralova 0, Roy M, Hall E, Shah SA, Cunanan K, Fardccn T, Velazquez B, Chu G. Bruzzonc B, Cabot A, Fisher GA, Srinivas S, Fan AC, Haraldsdottir S, Wakelce HA, Neal JW, Padda SK, Johnson T, Heestand GM, Hsieh RW, Ramchandran K. Implementation ofa cloud-based electronic patient-reported outcome (cPRO) platform in patients with advanced cancer. J Patient Rep Outcomes. 2021 Sep 15;5(1):91. doi: 10.I I 86/s41687-021-00358-2. PMID: 34524558.
3.  Das, M., Padcla, S.K., Weiss, J. Owonikoko, T. Advances in Treatment ofRecimcnt Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtabk Discussion. Adv 77,er, 2021 Sep 26:1-2 l. Doi: 10.1007/s12325-021-01909-1. Epub ahead of print PMID: 34564806; PMCID: PMC8475485.
4.  Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakclcc HA. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon l 9 Deletion Lung Cancer. Clin Lung Cancer. 2021 Oct 21:S1525-7304(21)00245-X. doi: 10.10I6/j.cllc.2021.09.004. Epub ahead of print. PMID: 34838441.
5.  l'adda SK, Reckamp KL, Koczywas M, Neal JW, Kawashima J, Kong S, Huang DB, Kowalski M, Wakelce HA. A Phase lb Study of Erlotinib and Momelotinih for the Treatment of EGFR-Mutated, Tyrosine Kinase Inhibitor-Naive Metastatic Non-Small Cell Lung Cancer. Cancer Chemotherapy and Pharmacology, 2021 Nov 13. Doi: 10.1007/s00280-021-04369-0. Online ahead of print. PMID: 34773474.
6.  White MN, Piper-Vallilo AJ, Gardner RM, Cunanan K, Neal JW, Das M, Padda SK, Ramchandran K, Chen TT, Sequist LV, Piotrowska Z, Wakelee HA. Chemotherapy plus immunotherapy or chemotherapy plus bcvacizumab versus chemotherapy alone in EGFR-mutant NSCLC after progression on osimertinib. Clinical Lung Cancer, 2021 Nov 11. Doi: JO.I 016/j.cllc.2021.11.001. Online ahead of print. PMID: 34887193.
7.    Aredo JV, Wakelce HA, Neal JW, Padda SK. Afatinib After Progression on Osimcrtinib in EGFR­ Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications. 2021 Dec 3;30:100497. doi: I0.1016/j.ctarc.2021.100497. Epub ahead of print. PMID: 34920242.
8.  Daly ME, Singh N, Ismaila N, AnlonoffMB, Arenberg DA, Bradley J, David E, Dctterbeck F, Frlih M, Gubens MA, Moore AC, Padda SK, Patel JD, Phillips T, Qin A, Robinson C, Simone CB 2nd. Management of Stage Ill Non-Small-Cell Lung Cancer: ASCO Guideline. Journal of Clinical Oncology. 2021 Dec 22:JCO2 I 02528. doi: 10.1200/JC0.21.02528. Epub ahead of print. PMID: 34936470.
9. Thomas S, Raj R, Hwang G, PancirerD, HornbackerKM, CodimaA, Lui NS, Kunz P, Padda SK. Diffuse Idiopathic Pulmonary Ncuroendocrinc Cell Hyperplasia (DIPNECH): Clinical Characteristics and Progression to Carcinoid Tumor. European Respiratory Journal. 2022 Jan: 59 (I) 210I058; doi: 10.l183/13993003.01058-2021
10.Singha! S, Hellyer J, Ouseph MM, Wakclec HA, Padda SK. Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. JTO Clin Res Rep. 2022 Apr 21;3(5):100323. doi: 10.1016/j.jtocrr.2022.100323. PMID: 35601925; PMCID: PMC9121321.

Additional Publications

I.    Padda S, Kothary N, Donington J, Cannon W, Loo BW Jr, Kee S, Wakclee H. Complications of ablative therapies in lung cancer. Clin Lung Cancer. 2008 Mar;9(2):122-6.
2.    Clement-Duchene C, Krupitskaya Y, Ganjoo K, Lavori P, McMillan A, Kumar A, Zhao G, Padda S, Zhou L, Pedro-Salcedo MS, Colevas AD, Wakelee HA. A phase II first-line study of gcmcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer. J Thorac Oneal. 2010 Nov;5(11):1821-5. (I was involved in consenting and accruing patients on this study, collating data, and reviewing the final manuscript.)
3.    Riess JW, Logan AC, Krupitskaya Y, Padda S, Clement-Duchene C, Ganjoo K, Colevas AD, Pedro­ Salcedo MS, Kuo CJ, Wakelce HA. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer. Cancer Invest. 2012 Mar;30(3):231-5. (I was involved in consenting and accruing patients on this study, collating data, and reviewing the final manuscript.)
4.    Padda SK, Krupitskaya Y, Chhatwani L, Fisher GA, Colevas AD, San Pedro-Salcedo M, Decker R, Latz JE, Wakelee HA. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2012
Apr;69(4): I 013-20.
5.    Riess JW, Padda SK, Bangs CD, Das M, Neal JW, Adrouny AR, Cherry A, Wakelee HA. A Case Series of Lengthy Progression-Free Survival with Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS I Gene Rearrangements. Clin Lung Cancer. 2013 Sep;l4(5):592-5. (I was involved in gathering the data along with both contributing to writing and reviewing the final manuscript.)
6.    Padda SK, Chhatwani L, Zhou L, Jacobs CD, Lopez-Anaya A, Wakelee HA. Phase I and pham1aeokinctic study ofbexarotene in combination with gefitinib in the third-line treatment ofnon­ small-cell lung cancer: briefreport. Anticancer Drugs. 2013 Aug;24(7):73 l-5.
7.    Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelce HA. Diffuse High Intensity PD-LI Staining in Thymic Epithelial Tumors. J Thorac Oneal. 2015 Mar;l0(3):500-8.
8.    Liang Y, Padda SK, Riess JW, West RB, Neal JW, Wakelee HA. Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. Lung Cancer. 2015 Jan;87(1):34-8. (I was involved in both contributing to writing and reviewing the final manuscript.)
9.    Das M', Padda SK', Frymoyer A, Zhou L, Riess JW, Neal JW, Wakelce HA. Dovitinib and crlotinib in patients with metastatic non-small cell lung cancer: A drug-drug interaction. Lung Cancer. 20I5 Sep;89(3):280-6. (*=co-first author)
10.    Padda SK, Shrager JB, Riess JW, Pagtama JY, Holmes Tisch AJ, Kwong BY, Liang Y, Schwartz EJ,
Loo BW, Neal JW, Hardy R, Wakelce HA. Pruritus as a Paraneoplastic Symptom ofThymoma. J Thorac Oneal. 2015 Nov;l0(l l):cl10-2.
11.    Burt BM, Yao X, Shrager J, Antonicclli A, Padda S, Reiss J, Wakelee H, Su S, Huang J, Scott W. Detcnninants of complete resection ofthymoma by minimally invasive and open thymeetomy: analysis of an international registry. J Thorac Oneal. 2017 Jan;l2(1):129-136. (I was involved in the project calls for development of the primary analysis for this database study along with editing and reviewing the final manuscript.)
12.    Chaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, Azad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, Scherer F, Kurtz DM, Say C, Carter JN, Merriott DJ, Dudley JC, Binkley MS, Modlin L, Padda SK, Gcnsheimer MF, West RB, Shragcr JB, Neal JW, Wakelee HA, Loo BW Jr, Alizadeh AA, Diehn M. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017 Dec;7(12):1394-1403. doi: 10.1158/2159- 8290.CD-17-0716. Epub 2017 Sep 24. (I was involved in accruing patients for this study along with editing and reviewing the final manuscript.)
13.    Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelcc HA, Badvc SS. Parancoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oneal. 2018 Mar;l3(3):436-446. doi: 10.1016/j.jtho.2017.l I.I 18. Epub 2017 Nov 27.
14.    Padda SK, Terrone D, Tian L, Khuong A, Neal JW, Riess JW, Berry MF, Hoang CD, Burt BM, Leung AN, Schwartz EJ, Shrager JB, Wakelce HA. Computed Tomography Features associated With the Eighth Edition TNM Stage Classification for Thymic Epithelial Tumors. J Thorac Imaging. 2018 May;33(3):176-183. doi: 10.1097/RTl.0000000000000310. Epub 2017 Dec 6.
15.    Das M, Padda SK, Frymoyer A, Molina J, Adjei A, Lensing JL, Miles D, Sikic Bl, Wakclee HA. A safety, tolerability, and phannacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intcnnittcnt and continuous dosing schedule in patients with advanced solid malignancies. Cancer Chemother Pharmacol. 2018 Sep;82(3):541-550. doi:10.1007/s00280-0l 8-3646-0. Epub 2018 Jul 20. (] was involved in data interpretation along with writing and editing the final manuscript.)
16.    Charvillc GW, Padda SK, Sibley RK, Puthillath A, Kwo PY. Resolution ofCrizotinib-Associatcd Fulminant Hepatitis following Cessation of Treatment. Case Reports Hepatol. 2018 Aug 5;2018:3413592. doi: 10. l 155/2018/3413592. eCollection 2018. (] was involved in data interpretation along with writing and editing the final manuscript.)
17.    Myall NJ, Henry S, Wood D, Neal JW, Han SS, Padda SK, Wakelee HA. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients with BRAF-Mutated Non-small-cell Lung Cancer. C/in Lung Cancer. 2019 Mar;20(2):e208-e2l 7. doi: I0.1016/j.clle.2018.10.003. Epub 2018 Oct 23. (I was involved in data interpretation along with editing the final manuscript.)
18.    Huang Y, Chow KKH, Aredo JV, Padda SK, Han SS, Kakusa BW, Hayden Gephart M. Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Caneer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study. World Neurosurg. 2019 Jan 31. pii: S1878-8750(19)30210-4. doi: 10.1016/j.wneu.2019.01.112. (I was involved in data interpretation along with editing the final manuscript.)
19.    Riess JW, Kong CS, West RB, Padda SK, Neal JW, Wakelee HA, Le QT. Increased Galectin-1 Expression in Thymic Epithelial Tumors. Clin Lung Cancer. 2018 Dec 21. pii: S1525- 7304(18)30329-2. doi: 10.1016/j.cllc.2018.12.005. [Epub ahead of print] (I was involved in data interpretation along with editing the final manuscript.)
20.    Sikic Bl, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients with Advanced Cancers. J Cliil Oncol. 2019 Feb 27:JCOl802018. doi: 10.1200/JCO.18.02018. [Epub ahead of print]
21.    Aredo JV, Padda SK, Kunder CA, Han SS, Neal JW, Shrager JB, Wakelee HA. Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer cutcomes. Lung Cancer. 2019 Jul;l33:144-150. doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15. PubMed
!'MID: 31200821. (I was involved in data interpretation along with contributing to writing/editing of the final manuscript)
22.    Hellyer JA, Stehr H, Das M, Padda SK, Ramchandran K, Neal JW, Diehn M, Wakele HA. Impact of KEAP I /NFE2L2/CUL3 mutations on duration ofresponse to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. Lung Cancer. 2019 Aug;134:42-45. doi: I0.1016/j.lungcan.2019.05.002. Epub 2019 May 3. PubMed PMID: 31319993. (I was involved in data interpretation along with editing the final manuscript).
23.    Morgensztem D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer. 2019 Jul;121(3):211-217. doi: 10.1038/s41416-019-0504-8. Epub 2019 Jun 24. PubMed PMID: 31231122;
24.    Jeong Y, Hellyer JA, Stehr H, Hoang NT, Niu X, Das M, Padda SK, Ramchandran K, Neal JW, Wakelee HA, Dielm M. Role ofKEAPl/NFE2L2 mutations in the chemotherapeutic response ofnon­ small cell lung cancer patients. Clin Cancer Res. 2019 Sep 23. pii: clincaures.1237.2019. doi: 10.1158/1078-0432.CCR-19-1237. [Epub ahead of print] PubMed PMID: 31548347 (: was involved in data interpretation along with editing the final manuscript).
25.    Hellyer JA, Gubens MA, Cunanan KM, Padda SK, Burns M, Spittler AJ, Riess JW, San Pedro­ Salcedo M, Ramchandran KJ, Neal JW, Wakelee HA, Loehrer PJ Sr. Phase II trial of single agent amrubicin in patients with previously treated advanced thymie malignancies. Lung Cancer. 2019 Sep 18;137:71-75. doi:10.1016/j.lungcan.2019.09.015. [Epub ahead of print] PubMed PMID: 31557562. (I was involved in data analysis, data interpretation, and editing the final manuscript).
26.    Hellmann MD, Nabet BY, Rizvi H, Chaudhuri AA, Wells DK, Dunphy MPS, Chaban JJ, Liu CL, Hui AB, Arbour KC, Luo J, Preeshagul IR, Moding EJ, Almanza D, Bonilla RF, Sauter JL, Choi H, Tenet M, Abn-Akeel M, Plodkowski AJ, Perez Johnston R, Yoo CH, Ko RB, Stehr H, Gojenola L, Wakelee HA, Padda SK, Neal JW, Chaft JE, Kris MG, Rudin CM, Merghoub T, Li BT, Alizadeh AA, Diehn M. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)l Blockade in NSCLC. Clin Cancer Res. 2020 Feb 11. doi: 10.1158/1078- 0432.CCR-19-3418. [Epub ahead of print] PubMed PMID: 32046999. (I was involved in the editing of the final manuscript)
27.    Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, LaidleyDT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. CommNETs/NANETS guidelines for the diagnosis and management of patients with Lung Neuroendocrine Tumors: An interna:ional collaborative endorsement and update of the 2015 ENETS expert consensus guidelines. J Thorne Oneal. 2020 Jul l l:Sl556-0864(20)30548-7. doi: 10.1016/j.jtho.2020.06.021. Epub ahead of print. PMID: 32663527. (I served on the committee that created these guidelines and was involved in the writing and editing of the final manuscript)
28.    Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chaban JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020 Oct 15;183(2):363-376.el3. doi: 10.1016/j.cell.2020.09.001. Epub 2020 Oct I. PMID: 33007267; PMCID: PMC7572899. (I provided patient translational samples and clinical correlation. I was involved in writing and editing of the final manuscript)
29.    Hellyer JA, Ouseph MM, Padda SK, Wakelee HA. Everolimus in the treatment of metastatic thymic epithelial tumors. Lung Cancer. 2020 Nov;l49:97-102. doi: 10.1016/j.lungcan.2020.09.006. Epub 2020 Sep 17. PMID: 33007678. (I was involved in data analysis along with writing and editing of final manuscript).
30.    Binkley MS, Jeon YJ, Nesselbush M, Moding EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, Xiang M, Chaban JJ, Hamilton E, Kurtz OM, Gojenola L, Owen SG, Ko RB, Shin JI-I, Maxim PG, Lui NS, Backhus LM, Berry MF, Shrager JB, Ramchandran KJ, Padda SK, Das M, Neal JW, Wakelee HA, Alizadeh AA, Loo BW Jr, Diehn M. KEAP!/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition. Cancer Discov. 2020 Dec;I0(l2):1826-1841. doi: I0.1158/2159-8290.CD-20-0282. Epub 2020 Oct 18. PMID: 33071215; PMCID: PMC7710558. (I provided patient translational samples and clinical correlation. I was involved in editing of the final manuscript)
31.    Nesvet JC, Antilla KA, Pancircr OS, Lozano AX, Preiss JS, Ma W, Fu A, Park SM, Gambhir SS, Fan AC, Neal JW, Padda SK, Das M, Li T, Wakelee HA, Wang SX. Giant Magnetoresisbve Nanosensor Analysis of Circulating Tumor DNA Epidernml Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. Clin Chem. 2021 Jan 4:hvaa307. doi: I 0.1093/clinchem/hvaa307. Epub ahead of print. PMID: 33393992. (I provided patient translational samples and clinical correlation. I was involved in editing of the final manuscript)
32.    Zhang M, Rodrigues AJ, Pollom EL, Gibbs IC, Soltys SG, Hancock SL, Neal JW, Padda SK,
Ramchandran KJ, Wakelee HA, Chang SD, Lim M, Hayden Gephart M, Li G. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-LI expressing non-small cell lung cancer with brain metastases. J Ncurooncol. 2021 Jan 7. doi:
I 0.1007/sl I 060-020-03686-3. Epub ahead of print. PMID: 33415659. (I was involved in data interpretation and writing/editing of the final manuscript)
33.    Padda SK, Aredo JV, Vali S, Singh NK, Vasista SM, Kumar A, Neal JW, Abbasi T, Wakclce HA. Computational Biological Modeling Identifies PD-(L) I Immunotherapy Sensitivity A:nong Molecular Subgroups of KRAS-Mutated Non-Small-Cell Lung Cancer. JCO Prccis Oneal. 2021 Nov;5:153-162. doi: I0.1200/PO.20.00172. PMID: 34994595.
34.    Hellyer JA, Aredo JV, Das M, Ramchandran K, Padda SK, Neal JW, Wakelec HA. Brief Report: Role of Consolidation Durvalumab in patients with EGFR and HER2 Mutant Unresectable Stage III NSCLC. J Thorac Oneal. 2021 Feb l:Sl556-0864(21)00044-7. doi: I0.1016/j.jtho.2020.12.020. Epub ahead of print. !'MID: 33539970. (I provided patient data, was involved in data interpretation and writing/editing of the final manuscript)
35.    Pathipati MP, Yohannan TK, Tian L, Hornbackcr K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer. 2021 Jan 23:S0169-5002(21)00035-0. doi: 10.1016/j.lungean.2021.01.017. Epub ahead of print. !'MID: 33551175.
36.    Aredo JV, Mambetsariev I, Hellyer JA, Amini A, Neal JW, Padda SK, Mccoach CE, Riess JW, Cabebe EC, Naidoo J, Abuali T, Salgia R, Loo BW Jr, Diehn M, Han SS, Wakelee HA. Durvalumab for Stage Ill EGFR-Mutated NSCLC After Definitive Chcmoradiothcrapy. J Thorac Oneal. 2021 Feb l2:Sl556-0864(21)01702-0. doi:  I0.1016/j.jtho.2021.01.1628. Epub ahead  of print. PMID: 33588109.
37.    Chiou SI-I, Tseng D, Reuben A, Mallajosyula V, Molina IS, Conley S, Wilhelmy J, McSween AM, Yang X, Nishimiya D, Sinha R, Nabct BY, Wang C, Shragcr JB, Berry MF, Backhus L, Lui NS, Wakelcc HA, Neal JW, Padda SK, Berry GJ, Dclaidelli A, Sorensen PH, Sotillo E, Tran P, Benson JA, Richards R, Labanieh L, Klysz DD, Louis DM, Feldman SA, Diehn M, Weissman IL, Zhang J, Wistuba 11, Futrcal PA, Heymach JV, Garcia KC, Mackall CL, Davis MM. Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity. 2021 Mar9;54(3):586-602.c8. doi: I0.1016/j.immuni.2021.02.014. PMID: 33691136; PMCID: PMC7960510.
38.    Waliany S, Neal JW, Reddy S, Wakelec H, Shah SA, Srinivas S, Padda SK, Fan AC, Colevas AD, Wu SM, Wittelcs RM, Zhu H. Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC CardioOncol. 2021 Mar;3(1):137-139. doi: 10.1016/j.jaccao.2021.01.004. Epub 2021 Mar 16. !'MID: 33796869; PMCID: PMC8009332.
39.    Nesvct JC, Antilla KA, Pancirer DS, Lozano AX, Preiss JS, Ma W, Fu A, Park SM, Gambhir SS, Fan AC, Neal JW, Padda SK, Das M, Li T, Wakelee HA, and Wang SX. Giant Magnctoresistive Nanosensor Analysis of ctDNA EGFR Mutations for Rapid Diagnosis and Therapy Response Monitoring. Clinical Chemistry. 2021 Mar!; 67(3): 534-542. doi: 10.1093/clinchem/hvaa307. PMID: 33393992.
40.    Padda SK, Giikmcn-Polar Y, Hellyer .IA, Badve SS, Singh NK, Vasista SM, Basu K, Kumar A, Wakelce I-IA. Genomic clustering analysis identifies molecular subtypes ofthymic cpi:helial tumors independent of World Health Organization histologie type. Oncotargct. 2021 Jun 8; I 2(12):1178- 1186. doi: 10.18632/oncotargct.27978. PMID: 34136086; PMCID: PMC8202771.
41.    Shah MP, Aredo JV, Padda SK, Ramchandran KJ, Wakelec HA, Das MS, Neal JW. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy. Clin Lung Cancer. 2021 Jul 19:SI 525-7304(21 )00182-0. doi: 10.1016/j.cllc.2021.07.001. Online ahead of print. PMID: 34391686. PMCID: PMC8766618.
42.    Wu J, Li C, Gensheimer M, Padda S, Kato F, Shirato H, Wei Y, Sch6nlieb CB, Price SJ, Jaffray D, Heymach J, Neal JW, Loo BW Jr, Wakelee H, Diehn M, Li R. Radiological tumor classification across imaging modality and histology. Nature Machine Intelligence. 2021 Sep;3:787-798. doi: 10.1038/s42256-02l-00377-0. Epub 2021 Aug 9. PMID: 34841195; PMCID: PMC8612063.
 

The following ratings and reviews are based on verified feedback collected from independently administered patient experience surveys. The ratings and comments submitted by patients reflect their own views and opinions. Patient identities are withheld to ensure confidentiality and privacy. Learn more about our Patient Experience Ratings.

Ratings Breakdown

Loading ...

Patient comments

Loading ...
​​